Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGb 761 for dementia prevention in elderly with memory complaints
NCT00276510Phase 4Completed
- Sponsor
- Ipsen
- Start
- Feb 2002
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ginkgo biloba extract in Alzheimer's disease (AD) (2 arms), sponsored by Ipsen. Primary endpoint: Conversion rate of memory complaint to dementia of Alzheimer type at 60 months. Started Feb 2002; status: completed.
02
Drugs
ginkgo biloba extract
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00276510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276510.